The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2017 | Enhancing autologous cellular therapy with ibrutinib in CLL patients
Iris de Weerdt, MD from the Academic Medical Center University of Amsterdam, Amsterdam, Netherlands provides an overview of her work on autologous cellular therapy at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY. Dr de Weerdt explains how Vgamma9Vdelta2 T-cells are able to recognise and kill tumour cells. However, their function is depressed in patients with chronic lymphocytic leukemia (CLL). When cellular therapy of Vgamma9Vdelta2 T-cells are combined with ibrutinib, the function of the T-cell improves such that it has enhanced anti-tumour cytokine ability.
